Dr. Reddy's Laboratories Ltd. closed 12.08% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr Reddy's Laboratories had received the manufacturing licence for semaglutide in December 2024 and it began production in ...

Dr. Reddy's Laboratories Ltd. closed 12.05% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Welcome to the Dr Reddys Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

Drug major, Dr. Reddy's Laboratories Ltd. has disclosed that it has received an order from the Income Tax Department under ...

Delhi High Court bars Dr Reddy's and OneSource from selling semaglutide in India, supporting Novo Nordisk's patent rights as ...

Dr. Reddy’s and OneSource agree not to sell Novo Nordisk’s anti-obesity drug in India amid patent infringement lawsuit.

Dr. Reddy’s Labs faces Rs. 2,395 crore tax demand, disputes reassessment linked to merger under amalgamation scheme.

The Delhi High Court declined to stop Dr. Reddy’s from manufacturing Novo Nordisk’s drug, but will continue to hear the ...

Dr Reddy's Laboratories' API plant in Telangana received two observations in a Form 483 during a recent inspection by the ...

Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of financial year ...